However, some patients fail to achieve the time-dependent endpoints of a complete hematologic response (CHR: the normalization of peripheral blood counts and resolution of splenomegaly and CML-related symptoms), complete cytogenetic response (CCyR: 0% Ph+ metaphases based on the analysis of 20 bone marrow cells), and major molecular response (MMR: BCR::ABL1 ≤ 0.1% on the international scale (IS)) (primary resistance), or lose response (secondary resistance), or experience intolerance [2,3]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.